Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | potassium voltage-gated channel, subfamily H (eag-related), member 2 | Starlite/ChEMBL | No references |
Homo sapiens | glucokinase (hexokinase 4) | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hexokinase family protein | glucokinase (hexokinase 4) | 465 aa | 470 aa | 30.0 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0031 | 0.0007 | 0.0123 |
Leishmania major | hexokinase, putative | 0.0096 | 0.0562 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0096 | 0.0562 | 1 |
Echinococcus multilocularis | hexokinase | 0.0096 | 0.0562 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 3 | 0.046 | 0.3638 | 0.326 |
Onchocerca volvulus | 0.0096 | 0.0562 | 1 | |
Toxoplasma gondii | cathepsin CPC2 | 0.046 | 0.3638 | 0.326 |
Trypanosoma brucei | hexokinase | 0.0096 | 0.0562 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.0075 | 0.134 |
Loa Loa (eye worm) | hypothetical protein | 0.0031 | 0.0007 | 0.0123 |
Loa Loa (eye worm) | hexokinase | 0.0096 | 0.0562 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0096 | 0.0562 | 1 |
Entamoeba histolytica | hexokinase 2 | 0.0096 | 0.0562 | 0.5 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0752 | 0.611 | 1 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0045 | 0.0125 | 0.2225 |
Brugia malayi | Hexokinase family protein | 0.006 | 0.0259 | 0.4604 |
Echinococcus granulosus | hexokinase | 0.0096 | 0.0562 | 1 |
Echinococcus multilocularis | hexokinase | 0.0096 | 0.0562 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0096 | 0.0562 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0066 | 0.0303 | 0.5396 |
Brugia malayi | hexokinase | 0.0096 | 0.0562 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.1213 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.0096 | 0.0562 | 1 |
Echinococcus granulosus | hexokinase type 2 | 0.0096 | 0.0562 | 1 |
Echinococcus granulosus | hexokinase | 0.0096 | 0.0562 | 1 |
Plasmodium vivax | dipeptidyl aminopeptidase 3, putative | 0.046 | 0.3638 | 0.326 |
Brugia malayi | hexokinase type II | 0.0031 | 0.0007 | 0.0123 |
Onchocerca volvulus | 0.0096 | 0.0562 | 1 | |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.1213 | 1 | 1 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.1213 | 1 | 1 |
Toxoplasma gondii | cathepsin CPC1 | 0.1213 | 1 | 1 |
Onchocerca volvulus | 0.0096 | 0.0562 | 1 | |
Schistosoma mansoni | dipeptidyl-peptidase I (C01 family) | 0.1213 | 1 | 1 |
Schistosoma mansoni | hexokinase | 0.0096 | 0.0562 | 0.0409 |
Leishmania major | hexokinase, putative | 0.0096 | 0.0562 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.006 | 0.0259 | 0.4604 |
Echinococcus granulosus | hexokinase | 0.0096 | 0.0562 | 1 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0045 | 0.0125 | 0.2225 |
Treponema pallidum | hexokinase (hxk) | 0.0096 | 0.0562 | 0.5 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.1213 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0096 | 0.0562 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0096 | 0.0562 | 1 |
Entamoeba histolytica | hexokinase 1 | 0.0096 | 0.0562 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0096 | 0.0562 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0096 | 0.0562 | 1 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.1213 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0096 | 0.0562 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 6.5 | Activity at glucokinase (unknown origin) | ChEMBL. | No reference |
IC50 (binding) | = 4.9 | Inhibition of human ERG | LITERATURE. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.